Product Description: Carfilzomib-d8 is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
Applications: Cancer-Kinase/protease
Formula: C40H49D8N5O7
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Dasmahapatra G, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep;10(9):1686-97./[3]Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90.
CAS Number: 1537187-53-3
Molecular Weight: 727.96
Compound Purity: 98.93
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Apoptosis;Autophagy;Isotope-Labeled Compounds;Proteasome
English
Deutsch
